Company News
JPMorgan Sets $32 Target for Hims & Hers
JPMorgan initiates coverage of Hims & Hers Health at Neutral with a December 2027 price target of $32 per share.
Analyst notes transition to branded GLP‑1 drugs, projecting 2026 GLP‑1 revenue of $1.1
